Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection

Annals of the Rheumatic Diseases

Volumn 72, Issue 2, 2013, Pages 308-310

  Mitroulis, Ioannnis ^a   Hatzara, Chrisoula ^b   Kandili, Anna ^b   Hadziyannis, Emilia ^b   Vassilopoulos, Dimitrios ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; METHOTREXATE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA;

ADULT; AGED; ANTIBODY TITER; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LETTER; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RHEUMATIC DISEASES; VIRUS ACTIVATION;

EID: 84872060358     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202088     Document Type: Letter

References (5)

1. Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57.
2. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5.
3. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011;70:1719-25.
4. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170-80.
5. Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-12.